Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate efficacy in the treatment of patients with rheumatoid arthritis in a randomized, double-blind placebo-controlled trial (Q36084912)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate efficacy in the treatment of patients with rheumatoid arthritis in a randomized, double-blind placebo-controlled trial |
scientific article |
Statements
1 reference
Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate efficacy in the treatment of patients with rheumatoid arthritis in a randomized, double-blind placebo-controlled trial (English)
1 reference
Dona L Fleishaker
1 reference
Juan A Garcia Meijide
1 reference
Andriy Petrov
1 reference
Michael David Kohen
1 reference
Xin Wang
1 reference
Sujatha Menon
1 reference
Thomas C Stock
1 reference
Charles A Mebus
1 reference
James M Goodrich
1 reference
Howard B Mayer
1 reference
Bernhardt G Zeiher
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference